ClinicalTrials.gg
CompletedNCT01625000Updated Jan 5, 2026Results posted

Safety and Efficacy of MP-214 in Patients With Schizophrenia

A Phase 2/3 interventional study of MP-214 3mg and MP-214 6mg in Schizophrenia, sponsored by Tanabe Pharma Corporation. Completed at 3 sites in 3 countries. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Tanabe Pharma Corporation · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
6th of 23
512 · median 129
Started
2012
with 4 others
Phase 2/3
6 of 23
1 open now
Registered
10th of 23
by date
Lead sponsor
6 of 23
Tanabe Pharma Corporation

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 6th largest by enrollment, is one of 5 that started in 2012, is one of 6 in phase 2/3, and was the 10th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Antipsychotic Agents
  • Acute Schizophrenia
  • Mental Disorder
  • Psychotropic Drugs
  • Dopamine Agents
  • Risperidone
  • Central Nervous System Agents
04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from the patient before the initiation of any study-specific procedures
  • Patients diagnosed with schizophrenia according to the diagnostic criteria of the , Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia
  • Patients with normal physical examination, laboratory, vital signs, and/or (ECG)

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
512 participants (actual)

Study arms

  • Experimental
    MP-214 3mg

    Drug: MP-214 3mg

  • Experimental
    MP-214 6mg

    Drug: MP-214 6mg

  • Experimental
    MP-214 9mg

    Drug: MP-214 9mg

  • Active comparator
    Risperidone 4mg

    Drug: Risperidone 4mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.

  • Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.

  • Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.

  • Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.

  • DrugPlacebo

    Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.

06

What researchers measure

Primary outcomes

  1. Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6

    PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6

    CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).

    Time frame: Baseline and Week 6

07

Results

Posted Apr 12, 2021

Participant flow

Participant flow — Overall Study
MilestoneMP-214 3mgMP-214 6mgMP-214 9mgRisperidone 4mgPlacebo
Started1261336756126
Completed7481343771
Not completed5252331955
Withdrew: Physician decision1577215
Withdrew: Protocol violation310412
Withdrew: Withdrawal by subject191611917
Withdrew: Adverse event (including death)151911721

Outcome measures

PrimaryChange in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6

PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
units on a scaleMP-214 3mgMP-214 6mgMP-214 9mgRisperidone 4mgPlacebo
Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6-10.4 ± 2.0-13.8 ± 2.0-14.0 ± 2.9-20.2 ± 3.0-9.5 ± 2.1
SecondaryChange in the Clinical Global Impression-Severity (CGI-S) Score at Week 6

CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6
units on a scaleMP-214 3mgMP-214 6mgMP-214 9mgRisperidone 4mgPlacebo
Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6-0.7 ± 0.1-0.8 ± 0.1-0.7 ± 0.2-1.2 ± 0.2-0.6 ± 0.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MP-214 3mg—12/126 (9.5%)95/126 (75.4%)
MP-214 6mg—16/133 (12%)100/133 (75.2%)
MP-214 9mg—4/67 (6%)52/67 (77.6%)
Risperidone 4mg—2/56 (3.6%)36/56 (64.3%)
Placebo—14/126 (11.1%)72/126 (57.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventMP-214 3mgMP-214 6mgMP-214 9mgRisperidone 4mgPlacebo
SchizophreniaPsychiatric disorders9/12614/1333/670/5612/126
AkathisiaNervous system disorders0/1260/1330/671/560/126
Extrapyramidal disorderNervous system disorders0/1260/1330/671/560/126
Suicide attemptPsychiatric disorders1/1260/1330/671/561/126
AgitationPsychiatric disorders0/1260/1331/670/560/126
Suicidal behaviourPsychiatric disorders0/1260/1331/670/560/126
Suicidal ideationPsychiatric disorders0/1260/1331/670/560/126
Infection maskedInfections and infestations0/1260/1330/670/561/126
PneumoniaInfections and infestations1/1260/1330/670/560/126
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1260/1330/670/560/126
Most frequent other events
Showing 10 of 21
Most frequent other events
EventMP-214 3mgMP-214 6mgMP-214 9mgRisperidone 4mgPlacebo
AkathisiaNervous system disorders28/12619/1332/679/5610/126
SchizophreniaPsychiatric disorders16/12615/13313/677/5623/126
ConstipationGastrointestinal disorders21/12620/13312/675/5615/126
Extrapyramidal disorderNervous system disorders11/12619/13311/676/5612/126
HeadacheNervous system disorders19/12614/1337/674/5614/126
VomitingGastrointestinal disorders18/12612/1335/671/567/126
NasopharyngitisInfections and infestations10/12615/1339/678/566/126
InsomniaPsychiatric disorders12/12616/1335/672/569/126
NauseaGastrointestinal disorders15/1269/1337/674/565/126
TremorNervous system disorders7/12613/1331/670/564/126

Baseline characteristics

Age, Continuous
Age, Continuous(years)MP-214 3mgMP-214 6mgMP-214 9mgRisperidone 4mgPlaceboTotal
Mean40.6 ± 10.640.2 ± 11.443.0 ± 9.739.5 ± 10.240.1 ± 11.140.6 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)MP-214 3mgMP-214 6mgMP-214 9mgRisperidone 4mgPlaceboTotal
Female6060342566245
Male6673333160263
08

Study locations

3 sites
  • Sapporo, Hokkaido, Japan
  • Seoul, South Korea
  • Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Aug 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2021, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2012
First posted
Jun 21, 2012
Start
May 2012
Primary completionActual
Aug 2015
CompletionActual
Oct 2015
Results first posted
Apr 12, 2021
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01625000
Responsible party
Sponsor
First posted
Jun 21, 2012
Start date
May 2012
Primary completion
Aug 2015
Completion
Oct 2015
Results posted
Apr 12, 2021
Last update
Jan 5, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion